Is AtriCure (ATRC) Fully Valued Following Its 70% Three Month Rally?

AtriCure (ATRC) has drawn fresh attention after a strong past 3 months, with the share price last closing at US$55.14 and the stock up 70.24% over that period.

Momentum in AtriCure looks punchy in the short term, with a 30 day share price return of 7.03% building on a 90 day gain of 70.24%. The 1 year total shareholder return of 58.40% contrasts with a weaker 5 year total shareholder return that is down 22.21%.

Compare AtriCure’s sharp rebound with other potential breakouts by reviewing our curated list of 19 high quality undiscovered gems in similar high-growth niches.

After a 70% three month surge and a value score of 1, AtriCure’s sharp swing in sentiment raises a simple question: Does the current price still compensate you for the risks on the table?

Most Popular Narrative: 1% Overvalued

AtriCure’s most followed narrative now pegs fair value at about $54.89, almost exactly in line with the recent $55.14 close. This leaves very little room for error in the story that underpins the stock.

The successful completion of enrollment in the LeAAPS clinical trial, as well as early activation of the BoxX-NoAF study, are set to substantially increase AtriCure's total addressable market if positive outcomes lead to expanded indications for stroke prevention and preventative cardiac surgery in underserved populations, which will support future revenue and earnings growth.

See why 5 investors see AtriCure as 0% overvalued.

Result: Fair Value of $54.89 (OVERVALUED)

Still, parts of the AtriCure story could crack if pulsed field ablation takes more share than expected, or if high R&D spending fails to translate into revenue.

Find out about the key risks to this AtriCure narrative.

Next Steps

Mixed signals on AtriCure so far. If you want your view to be grounded in the full picture, take a few minutes to scan both the risks and the upside, and then review the 2 key rewards and 1 important warning sign.

Want more ideas beyond AtriCure?

If AtriCure’s surge has you thinking bigger, do not stop with a single ticker. Use the screener to surface fresh ideas before other investors crowd in.

• Target resilient businesses first and filter for 31 resilient stocks with low risk scores that keep risk scores in focus while still leaving room for upside.
• Hunt for quality at a sensible entry point by scanning 31 high quality undervalued stocks that pair solid fundamentals with more modest pricing.
• Strengthen the foundation of your portfolio and shortlist companies from the list of solid balance sheet and fundamentals (25 results) that keep debt and cash in tighter control.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com